1 / 42

Community acquired pneumonia

Community acquired pneumonia. A/Prof Peter Wark Department of Respiratory and Sleep Medicine John Hunter Hospital. Ms AN, 37 year old Previously well 3 day history Sore throat Dry cough Today Left sided sharp chest pain Felt hot and unwell, rigors. Differential diagnosis. Pneumonia

jamuna
Download Presentation

Community acquired pneumonia

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Community acquired pneumonia A/Prof Peter Wark Department of Respiratory and Sleep Medicine John Hunter Hospital

  2. Ms AN, 37 year old • Previously well • 3 day history • Sore throat • Dry cough • Today • Left sided sharp chest pain • Felt hot and unwell, rigors

  3. Differential diagnosis • Pneumonia • Bronchitis • Asthma • Pulmonary embolus

  4. Epidemiology • In US pneumonia • 6th leading cause of death • Leading cause of death from an infectious disease • Mortality • 1-5% • Up to 40%

  5. Identifying a pathogen

  6. Identifying a pathogen • In clinical practice an organism is found in only 50% • No single test is available that can identify all organisms • History, clinical findings and X-ray changes are not diagnostic of a particular organism • ? Mixed infection, especially viral and bacterial

  7. CAP, no history of significant chronic disease • 20-60%, Strep Pneumoniae • 3-37%, Mycoplasma Pneumoniae and Chlamydia Pneumoniae • 10% cases • Viral (exceptions influenza, adenovirus) • Staph Aureus (MSSA and MRSA) • Gram neg organisms • Legionella pneumophilia (3-10%)

  8. CAP and co-morbid diseases • Risk is increased • Nursing home resident • Cardiorespiratory disease (COPD, CCF) • Immunosuppression • Alcoholism • Recent antibiotic use • Age > 65 years • Cause • more gram negative organisms or resistant pathogens • Viral (CMV, VSZ, respiratory viruses • PCP • Fungal

  9. Severe CAP • 20-50%, Strep Pneumoniae • 10-30% E.Coli, K Pneumoniae, Enterobacter • 3-10% Legionella pneumophilia (adm ICU) • Staph Aureus • MSSA • MRSA • Viral • Pseudomonas Aerugniosa ?

  10. Viral pneumonia • PCR improves detection • Some series, accounts for up to 24% • Not predicted by CXR or CRP • Pathogens • Influenza • SARS • RSV • Rhinovirus (co-pathogen 35% severe CAP) • Adenovirus

  11. How to identify the pathogen?

  12. Sputum • Sensitivity 10-54% • “good sample” and cultured quickly • Gram stain positive (esp Pneumococcus) • Culture best with heavy growth and correlation with gram stain • Special culture medium for Legionella, sensitivity 10-80% (better with BAL), specificity 80% • High false positive, especially Staph Aureus & GNB

  13. Blood cultures • Sensitivity 7-16%, specificity 90% (depends on organism) • Strep Pneumoniae, • accounts for 2/3 positive blood cultures • Pneumococcal bacteraemia, 1%, mortality 19% vs 4% hospitalised with pneumococcal pneumonia

  14. Urinary antigens • Detection of Strep Pneumoniae & Legionella • Advantages • Easily available • Valid after antibiotics initiated • Pneumococcus • Sensitivity 82%, specificity 97% (bacteraemic) • Legionella • Sensitivity 70-80%, specificity 97% • Only L. Pneumophilia

  15. Severity scoring • CURB-65 • Confusion (1 point) • Urea >7mmols (1) • Respiratory rate >30 (1) • BP, systolic <90 or diastolic < 60 (1) • Age >65yrs

  16. PSI in adults Sex M (0 points) F (-10 points) Demographic factors Age (1 point for each year) Nursing home resident (10 points) Physical examination findings Altered mental status (20 points) Respiratory rate >= 30/minute (20 points) Systolic blood pressure < 90 mmHg (20 points) Temperature < 35 degrees C or >= 40 degrees C (15 points) Pulse >= 125/minute (10 points) Comorbid illnesses Neoplastic disease (30 points) Liver disease (20 points) Congestive heart failure (10 points) Cerebrovascular disease (10 points) Renal disease (10 points)

  17. PSI in adults Laboratory and radiographic findings Arterial pH < 7.35 (30 points) Blood urea nitrogen >= 30 mg/dL (11 mmol/L) (20 points) Sodium < 130 mEq/L (20 points) Glucose 14 mmol/L) (10 points) Hematocrit < 30 percent (10 points) Partial pressure of arterial oxygen < 60 mmHg or oxygen saturation < 90% (10 points) Pleural effusion (10 points)

  18. PSI and assessment

  19. Assessment; co-morbidities • Age >65yrs • Chronic disease • COPD • CCF • Diabetes • Liver disease • Chronic renal failure • Neoplasia • Alcoholism • Immunosuppression

  20. Assessment examination • Altered mental state • Tachypnoea (RR>30) • Hypotension (systolic <90mmHg) • Temperature <350C or > 40oC • Tachycardia (125bpm)

  21. Assessment, investigations • Electrolytes • Na <130mmol • Glucose >14mmol • Renal impairment (Urea >11mmol/L) • Gas exchange and acid base • pH <7.35 • PaO2 <60mmHg • CXR • Extent consolidation • Presence of an effusion

  22. Ms AN Clinical Investigations pH 7.38 pO2 68mmHg Na 135mmols HCT 32% Urea 8mmols BGL 8mmols No effusion • Age 39 years • No co-morbidities • Altered mental state • BP 100/50 • Temp, 39.5 • RR, 32bpm • HR 125 Score 104 Class 4 mortality 9.3%

  23. Management

  24. Empirical antibiotics • Moderate • Penicillin 1.2g 4hrly IV + • Doxycycline or clarithromycin or azithromycin orally • If gram negative, add gentamicin for 2-3 doses (7mg/kg/d) • Severe • Penicillin 1.2g IV 6hrly + • Gentamicin IV 2-3 doses + • Azithromycin 500mg IV • Alternate • Ceftriaxone 1g/d or • Tazocin 4.5gm QID • Moxifloxacin 400mg IV/PO daily

  25. Outcomes with empirical antibiotics (Asadi et al Resp Med 2012 • 2973 patients mild pneumonia • Those who received guideline based treatment, less likely to die, 6% v 1% (OR 0.23, 0.09 to 0.59) • Those who received macrolides (as opposed to fluroquinolones) were less likely to die.

  26. Watching the clinical response

  27. The usual response • 24-72 hrs, see stability • Day 3, • improvements in symptoms • Defervescence by day 4 (most rapid Strep Pneumoniae) • Fall in WCC & CRP or 50% reduction PCT • CXR • Slow to resolve (60% some abnormality at 4 weeks)

  28. Responders 48 to 72hrs • Switch to PO therapy • Improvement in cough and dyspnoea • Afebrile • WCC & CRP improving • Discharge • No need to repeat CXR now, but 4-6 weeks post discharge

  29. Procalcitonin in CAP • PCT >0.25 mcg/L and decision to use antibiotics reduces unnecessary antibiotic use in 2 RCTs • Improves diagnosis in those with heart failure • Cost effective in ICU • Higher PCT predicts the presence of bacteraemia • Increase in PCT in first 72hrs was associated with reduced survival • Fall in PCT by 50% indicates an ability to switch to PO antibiotics

  30. PCT and CURB-65

  31. Early clinical response Lack of clinical response Deteriorating Switch to oral & discharge Revaluate Host Pathogen Complications Progress 24-72hrs clinical response

  32. Failure to respond

  33. Host factors Elderly Immunosuppressed Bacteraemia Chronic illness Diabetes Alcoholism Second nosocomial pneumonia Misdiagnosis Pulmonary embolus CCF Pulmonary haemorrhage Pulmonary vasculitis BOOP Acute interstitial pneumonitis Eosinophilic pneumonia Hypersensitivity pneumonitis Lack of response or deterioration • Local factors • Effusion/empyema • Abscess

  34. Called to Ms AN • Agitated and very breathless • P 140, BP 90/50, RR 38, T 390C • ABGs (FiO2 0.5) • pH 7.32 • PaO2 55mmHg • PaCO2 30mmHg • HCO3 16mmols

  35. Called to see Ms AN • Agitated and very breathless • P 140, BP 90/50, RR 38, T 390C • ABGs (FiO2 0.5) • pH 7.32 • PaO2 55mmHg • PaCO2 30mmHg • HCO3 16mmols

  36. The cause? • Progression of pneumonia • ARDS • Bacteraemia • Shock

  37. Empyema • Suspect • Persistent fever • Pleuritic chest pain • Organisms (pneumococcous, Strep Milleri, Staph Aureus) • Clinical examination • Image again

  38. Empyema

  39. Lung abscess/necrotising pneumonia

  40. Conclusions • Clinical assessment • Diagnosis with CXR • Risk factors for poor outcomes • Severity assessment • Follow guidelines for empirical antibiotics • Assess response • Reassess if response is not typical

More Related